Vaxxinity, Inc. (VAXX): Price and Financial Metrics

Vaxxinity, Inc. (VAXX): $0.00

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add VAXX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#255 of 360

in industry

VAXX Price/Volume Stats

Current price $0.00 52-week high $1.10
Prev. close $0.00 52-week low $0.00
Day low $0.00 Volume 2,900
Day high $0.00 Avg. volume 759,004
50-day MA $0.02 Dividend yield N/A
200-day MA $0.23 Market Cap 25.35K

VAXX Stock Price Chart Interactive Chart >


Vaxxinity, Inc. (VAXX) Company Bio


Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.


VAXX Latest News Stream


Event/Time News Detail
Loading, please wait...

VAXX Latest Social Stream


Loading social stream, please wait...

View Full VAXX Social Stream

VAXX Price Returns

1-mo 0.00%
3-mo 0.00%
6-mo 0.00%
1-year 0.00%
3-year 0.00%
5-year N/A
YTD 0.00%
2023 -39.29%
2022 -75.04%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!